Analyzing Ambrx Biopharma Inc. (AMAM)’s financial ratios for investment purposes

As of close of business last night, Ambrx Biopharma Inc.’s stock clocked out at $14.23, up 5.56% from its previous closing price of $13.48. In other words, the price has increased by $+0.75 from its previous closing price. On the day, 712481 shares were traded. AMAM stock price reached its highest trading level at $15.09 during the session, while it also had its lowest trading level at $13.54.

Top 5 EV Tech Stocks to Buy for 2023

According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.

Click Here to Download the FREE Report.



To gain a deeper understanding of AMAM’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.10 and its Current Ratio is at 10.10. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 20 when Cormorant Asset Management, LP bought 886,634 shares for $11.60 per share. The transaction valued at 10,285,220 led to the insider holds 67,313,085 shares of the business.

Cormorant Asset Management, LP bought 951,909 shares of AMAM for $10,612,357 on Apr 19. The 10% Owner now owns 66,426,451 shares after completing the transaction at $11.15 per share. On Apr 18, another insider, Cormorant Asset Management, LP, who serves as the 10% Owner of the company, bought 3,376,646 shares for $11.27 each. As a result, the insider paid 38,053,112 and bolstered with 65,474,542 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AMAM now has a Market Capitalization of 751.12M and an Enterprise Value of 605.10M. For the stock, the TTM Price-to-Sale (P/S) ratio is 143.53 while its Price-to-Book (P/B) ratio in mrq is 3.50. Its current Enterprise Value per Revenue stands at 104.09 whereas that against EBITDA is -8.42.

Stock Price History:

Over the past 52 weeks, AMAM has reached a high of $14.60, while it has fallen to a 52-week low of $0.38. The 50-Day Moving Average of the stock is 10.45, while the 200-Day Moving Average is calculated to be 4.22.

Shares Statistics:

It appears that AMAM traded 2.76M shares on average per day over the past three months and 691.48k shares per day over the past ten days. A total of 45.00M shares are outstanding, with a floating share count of 5.52M. Shares short for AMAM as of Apr 27, 2023 were 747.75k with a Short Ratio of 0.75M, compared to 889k on Mar 30, 2023.

Earnings Estimates

As of right now, 0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.

Analysts are recommending an EPS of between -$0.28 and -$0.29 for the fiscal current year, implying an average EPS of -$0.28. EPS for the following year is -$0.2, with 3 analysts recommending between -$0.18 and -$0.22.

Revenue Estimates

A total of 3 analysts have provided revenue estimates for AMAM’s current fiscal year. The highest revenue estimate was $7.4M, while the lowest revenue estimate was $5.82M, resulting in an average revenue estimate of $7.4M. In the same quarter a year ago, actual revenue was $7.46M, down -0.70% from the average estimate. Based on 3 analysts’ estimates, the company’s revenue will be $3.59M in the next fiscal year. The high estimate is $7.66M and the low estimate is $100k. The average revenue growth estimate for next year is down -51.50% from the average revenue estimate for this year.